Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Change in Account Payables: 2009-2025

Historic Change in Account Payables for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to $54,437.

  • China Pharma Holdings' Change in Account Payables fell 77.67% to $54,437 in Q3 2025 from the same period last year, while for Sep 2025 it was $202,297, marking a year-over-year increase of 143.02%. This contributed to the annual value of -$733,916 for FY2024, which is 335.20% down from last year.
  • As of Q3 2025, China Pharma Holdings' Change in Account Payables stood at $54,437, which was up 381.74% from -$19,322 recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Change in Account Payables registered a high of $442,807 during Q3 2023, and its lowest value of -$505,339 during Q2 2024.
  • Over the past 3 years, China Pharma Holdings' median Change in Account Payables value was $54,437 (recorded in 2025), while the average stood at -$5,802.
  • As far as peak fluctuations go, China Pharma Holdings' Change in Account Payables surged by 3,045.77% in 2023, and later plummeted by 414.87% in 2024.
  • China Pharma Holdings' Change in Account Payables (Quarterly) stood at $311,018 in 2021, then declined by 23.32% to $238,485 in 2022, then slumped by 54.75% to $107,922 in 2023, then tumbled by 244.32% to -$155,753 in 2024, then tumbled by 77.67% to $54,437 in 2025.
  • Its Change in Account Payables stands at $54,437 for Q3 2025, versus -$19,322 for Q2 2025 and $322,935 for Q1 2025.